Du QC, Wang XY, Yu H. Gastric cancer immunotherapy: A scientometric and clinical trial review. World J Gastroenterol 2024; 30(2): 196-198 [PMID: 38312117 DOI: 10.3748/wjg.v30.i2.196]
Corresponding Author of This Article
Hua Yu, MM, Associate Chief Physician, Department of General Surgery, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, No. 1279 Sanmen Road, Hongkou District, Shanghai 200434, China. luckyyuhua@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 14, 2024; 30(2): 196-198 Published online Jan 14, 2024. doi: 10.3748/wjg.v30.i2.196
Gastric cancer immunotherapy: A scientometric and clinical trial review
Qian-Cheng Du, Xin-Yu Wang, Hua Yu
Qian-Cheng Du, Thoracic Surgery, Shanghai Xuhui Central Hospital, Shanghai 200031, China
Xin-Yu Wang, Thyroid, Breast and Vascular Surgery, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China
Hua Yu, Department of General Surgery, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China
Author contributions: Du QC and Wang XY contributed equally in analysis of the data and writing of the manuscript; Yu H designed the article and corrected the paper; and all authors have read and approved the final manuscript.
Supported bythe Discipline Promotion Program of Shanghai Fourth People’s Hospital, No. SY-XKZT-2020-1021.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hua Yu, MM, Associate Chief Physician, Department of General Surgery, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, No. 1279 Sanmen Road, Hongkou District, Shanghai 200434, China. luckyyuhua@163.com
Received: November 11, 2023 Peer-review started: November 11, 2023 First decision: December 20, 2023 Revised: December 21, 2023 Accepted: December 28, 2023 Article in press: December 28, 2023 Published online: January 14, 2024 Processing time: 61 Days and 17.8 Hours
Abstract
This letter is intended to arouse your interest in a recent review of comprehensive scientometrics and clinical trials on immunotherapy for gastric cancer (GC). Our study reviews recent advances in immunotherapy in the field of GC and highlights its new prospects as a treatment for GC. Our research reveals China’s leadership in this field, as well as new therapeutic strategies such as immune checkpoint inhibitors, cellular immunotherapy, and vaccines. The combined findings highlight the potential of immunotherapy to improve survival and quality of life in patients with stomach cancer. We believe that this study will provide important guidance for the future direction of the GC treatment field.
Core Tip: The article is a comprehensive review of immunotherapy for gastric cancer (GC), emphasizing the leadership of immunotherapy in the field of GC. The paper focuses on new strategies such as immune checkpoint inhibitors, cellular immunotherapy, and vaccines, highlighting their potential in improving the survival and quality of life of GC patients. This study provides crucial guidance for the future development direction of GC treatment and valuable insights into emerging therapeutic approaches.
